FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380029477> ?p ?o ?g. }

• W4380029477 endingPage "5465" @default.
• W4380029477 startingPage "5465" @default.
• W4380029477 abstract "Abstract Background: Hepatocellular carcinoma (HCC) is one of the major causes for cancer-related death. Single agent immunotherapy or combined immunotherapy have become the standard of care in advanced HCC. Recently, the combination of durvalumab (dur) plus a single dose of 300 mg tremelimumab (trem) (STRIDE regimen) have received FDA approval based on results from the HIMALAYA trial. However, immune responses have not been studied in detail. We tested the combination of 4 × 75 mg trem plus dur and locoregional therapies in HCC at and conducted correlative studies. Methods: We enrolled 28 patients with biopsy proven advanced HCC in an open-labeled phase 2 trial using dur and trem combined with ablative therapies (NCT02821754). Patients received four doses of 75mg trem every 4 weeks and 1500mg dur every 4 weeks until progression. Patients underwent an interventional radiologic procedure (RFA/TACE) on day 36. Peripheral blood mononuclear cells (PBMC) and serum from patients enrolled were collected at baseline and after 1 cycle (day 28). PBMC was analyzed by multicolor spectral cytometry using a 17 antibody pan immune cell panel and a 25 antibody T cell panel. Serum samples from patients were collected at baseline and on day 28. Serum samples were analyzed with a 34-plex cytokine/chemokine array. Mice with orthotopically injected HCC (RIL-175 and Hep55.1C) were treated with anti-PD-L1 plus anti-CTLA4 and followed for tumor responses. Hepatic lymphocytes, tumor infiltrating lymphocytes (TILs), and splenocytes were analyzed by spectral cytometry from mice treated with immune checkpoint inhibitors. Results: 28 patients with advanced HCC were enrolled in this study. The best clinical response for treatment was the following, partial response (PR, n=5), stable disease (SD, n=12), progressive disease (PD, n=8), and not evaluable (n=3). Median PFS and OS were 4.5 and 20.8 months respectively. Patient PBMC analysis demonstrated an increase of regulatory T cells 1.65 times from baseline after 28 days in all patients. The frequency of Tbet+CD4+ T cells showed a non-significant increase in patients demonstrating a PR. Serum cytokine analysis revealed the levels of IL-18, IL-10, CCL-2, and VEGF-a increased in responders after treatment. in contrast, an increase of IL-6 and TNF-alpha after treatment was found only in patients with PD. In animal experiments, the size of liver tumors treated with anti-PDL1 and anti-CTLA4 were significantly smaller than that with isotype controls. The lymphocytes in the adjacent livers and tumor-infiltrating lymphocytes (TILs) were analyzed. PD1+CD8+ T cells and Tbet+CD4+ T cells in the liver and TILs increased with combination treatment. Conclusion: Anti-PD-L1 and anti-CTLA4 combination therapy have an anti-tumor effect on HCC. We observed an expansion of PD1+ CD8+ T cells and Tbet+ CD4+ T cells. Citation Format: Yuta Myojin, Benjamin Ruf, Mohamed-Reda Benmebarek, Kylynda Bauer, Rajiv Trehan, Kelley Coffman, Chi Ma, Cecilia B. Monge, Changqing Xie, Tim Greten. Immune cell dynamics of patients and mice with hepatocellular carcinoma treated with anti-PD-L1 plus anti-CTLA-4 combination therapy. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5465." @default.
• W4380029477 created "2023-06-10" @default.
• W4380029477 creator A5025086832 @default.
• W4380029477 creator A5025405931 @default.
• W4380029477 creator A5043042941 @default.
• W4380029477 creator A5047331780 @default.
• W4380029477 creator A5050385258 @default.
• W4380029477 creator A5057207921 @default.
• W4380029477 creator A5067311792 @default.
• W4380029477 creator A5078103351 @default.
• W4380029477 creator A5080512785 @default.
• W4380029477 creator A5084094076 @default.
• W4380029477 date "2023-04-04" @default.
• W4380029477 modified "2023-09-27" @default.
• W4380029477 title "Abstract 5465: Immune cell dynamics of patients and mice with hepatocellular carcinoma treated with anti-PD-L1 plus anti-CTLA-4 combination therapy" @default.
• W4380029477 doi "https://doi.org/10.1158/1538-7445.am2023-5465" @default.
• W4380029477 hasPublicationYear "2023" @default.
• W4380029477 type Work @default.
• W4380029477 citedByCount "0" @default.
• W4380029477 crossrefType "journal-article" @default.
• W4380029477 hasAuthorship W4380029477A5025086832 @default.
• W4380029477 hasAuthorship W4380029477A5025405931 @default.
• W4380029477 hasAuthorship W4380029477A5043042941 @default.
• W4380029477 hasAuthorship W4380029477A5047331780 @default.
• W4380029477 hasAuthorship W4380029477A5050385258 @default.
• W4380029477 hasAuthorship W4380029477A5057207921 @default.
• W4380029477 hasAuthorship W4380029477A5067311792 @default.
• W4380029477 hasAuthorship W4380029477A5078103351 @default.
• W4380029477 hasAuthorship W4380029477A5080512785 @default.
• W4380029477 hasAuthorship W4380029477A5084094076 @default.
• W4380029477 hasConcept C121608353 @default.
• W4380029477 hasConcept C126322002 @default.
• W4380029477 hasConcept C137061746 @default.
• W4380029477 hasConcept C143998085 @default.
• W4380029477 hasConcept C185592680 @default.
• W4380029477 hasConcept C202751555 @default.
• W4380029477 hasConcept C203014093 @default.
• W4380029477 hasConcept C2777701055 @default.
• W4380029477 hasConcept C2777742743 @default.
• W4380029477 hasConcept C2778019345 @default.
• W4380029477 hasConcept C2780030458 @default.
• W4380029477 hasConcept C2781413609 @default.
• W4380029477 hasConcept C55493867 @default.
• W4380029477 hasConcept C71924100 @default.
• W4380029477 hasConcept C8891405 @default.
• W4380029477 hasConcept C90924648 @default.
• W4380029477 hasConceptScore W4380029477C121608353 @default.
• W4380029477 hasConceptScore W4380029477C126322002 @default.
• W4380029477 hasConceptScore W4380029477C137061746 @default.
• W4380029477 hasConceptScore W4380029477C143998085 @default.
• W4380029477 hasConceptScore W4380029477C185592680 @default.
• W4380029477 hasConceptScore W4380029477C202751555 @default.
• W4380029477 hasConceptScore W4380029477C203014093 @default.
• W4380029477 hasConceptScore W4380029477C2777701055 @default.
• W4380029477 hasConceptScore W4380029477C2777742743 @default.
• W4380029477 hasConceptScore W4380029477C2778019345 @default.
• W4380029477 hasConceptScore W4380029477C2780030458 @default.
• W4380029477 hasConceptScore W4380029477C2781413609 @default.
• W4380029477 hasConceptScore W4380029477C55493867 @default.
• W4380029477 hasConceptScore W4380029477C71924100 @default.
• W4380029477 hasConceptScore W4380029477C8891405 @default.
• W4380029477 hasConceptScore W4380029477C90924648 @default.
• W4380029477 hasIssue "7_Supplement" @default.
• W4380029477 hasLocation W43800294771 @default.
• W4380029477 hasOpenAccess W4380029477 @default.
• W4380029477 hasPrimaryLocation W43800294771 @default.
• W4380029477 hasRelatedWork W1741544496 @default.
• W4380029477 hasRelatedWork W1996150995 @default.
• W4380029477 hasRelatedWork W2023771859 @default.
• W4380029477 hasRelatedWork W2380021556 @default.
• W4380029477 hasRelatedWork W2381196212 @default.
• W4380029477 hasRelatedWork W2763883091 @default.
• W4380029477 hasRelatedWork W3180780036 @default.
• W4380029477 hasRelatedWork W4291367166 @default.
• W4380029477 hasRelatedWork W4360983034 @default.
• W4380029477 hasRelatedWork W1564894628 @default.
• W4380029477 hasVolume "83" @default.
• W4380029477 isParatext "false" @default.
• W4380029477 isRetracted "false" @default.
• W4380029477 workType "article" @default.